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doi:10.1016/j.jfma.2011.05.010Background/Purpose: The emergence of lamivudine (LAM)-resistant mutants after prolonged
LAM therapy may reduce its therapeutic effects against hepatitis B virus (HBV). Adefovir dipi-
voxil (ADV) is an effective treatment of LAM-resistant HBV infections. However, only limited
data are available regarding the safety and efficacy of ADV for treating HBsAg-positive renal
transplant recipients.
Methods: Fourteen HBsAg-positive patients who underwent renal transplantation and devel-
oped the YMDD mutation after prolonged LAM therapy were retrospectively analyzed. Five
patients were administered ADV monotherapy, while nine patients received ADV plus LAM
combination therapy. Data on age, gender, duration of previous LAM treatment, pre-LAM
HBV DNA and liver enzyme levels, duration of LAM treatment prior to the emergence of muta-
tions, duration of ADV rescue therapy, and the clinical outcomes of treatment (i.e., normali-
zation of alanine transaminase (ALT) and undetectable HBV DNA levels) were analyzed.
Results: The mean age of the patients was 46.8  11.5 years. Males were predominantly
studied. The mean follow-up duration of rescue therapy was 38.2  18.3 months. At the begin-
ning of rescue therapy, the mean serum ALT level was 142.2  99.8 IU/mL, while the median
serum level of HBV DNA was 7.85 log10 copies/mL. Patients who received combination therapy
tended to demonstrate undetectable serum HBV DNA levels, but no significant differences inrformed the study, complied and analyzed the data, and wrote the manuscript; TY Chen, CC Chang,
cted and analyzed the data, and wrote the manuscript; and TH Chen and MC Tsai collected the data
care of the patients.
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440 H.-W. Lai et al.terms of clinical outcomes were observed between patients who received ADV monotherapy
and patients who received combination therapy. After 12 months of treatment, 13 patients
(92.8%) developed normalized ALT levels. Five (35.7%) and six (42.8%) patients achieved unde-
tectable serum HBV DNA levels after 12 months and 24 months of treatment, respectively. No
virological breakthroughs were observed. Twenty-nine percent of the patients developed
moderate to severe renal insufficiency.
Conclusion: Although no statistical difference was noted, ADV plus LAM combination therapy
tended to demonstrate a higher therapeutic efficacy than ADV monotherapy for treating
LAM-resistant HBV infection in renal transplant recipients. Renal function should be closely
monitored in order to ameliorate nephrotoxicity.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Immunosuppression seems to enhance the replication of the
hepatitis B virus (HBV) and accelerate the progression of liver
disease.1 Flare ups of hepatitis in chronic HBV patients
receiving immunosuppressive agents after renal trans-
plantation are common and life-threatening events.2e4 The
persistent suppression of HBV with prolonged antiviral
therapy is always mandatory in these patients. Lamivudine
(LAM) is considered the drug of choice for the treatment of
posttransplant HBV infections and has shown good
biochemical and virological responses.5 However, the
emergence of resistantmutants after prolonged LAM therapy
for HBV infection may reduce its therapeutic effects.6
The vast majority of patients with confirmed LAM resis-
tance should receive rescue therapy with antiviral agents
that are effective against LAM-resistant HBV mutants.7
Adefovir dipivoxil (ADV), a nucleotide analog of adenosine
monophosphate, is an effective treatment against LAM-
resistant HBV infections. However, whether or not
therapy with combination ADV plus LAM improves the
response rate in comparison with ADV monotherapy
remains debatable. In a pilot study on patients with
compensated chronic HBV and LAM resistance, no differ-
ences between HBV DNA suppression and alanine trans-
aminase (ALT) normalization were observed between
patients treated with combination LAM plus ADV and
patients treated with ADV alone.8 Recent studies show that
switching to ADV alone in patients with LAM-resistant HBV is
associated with a higher risk of ADV resistance compared
with simply adding ADV to the treatment regimen.9,10
However, to date there are limited data available on the
efficacy and safety of ADV for treating HBV-positive renal
transplant recipients.
In this study, we retrospectively evaluated and
compared the therapeutic efficacy and safety of ADV
monotherapy and LAM plus ADV combination therapy in
LAM-resistant HBsAg-positive renal transplant recipients.
Methods
We retrospectively reviewed the medical records of 765
renal transplant recipients who received regular follow-up
visits at Chung Shan Medical University Hospital between
January 2003 and December 2007. Twenty-seven HBsAg-
positive patients received anti-HBV treatment during thestudy period. In Taiwan in October 2003, the national
healthcare budget only allowed LAM therapy pending HBV
reactivation and the presence of necrosis or inflammation
of the liver (i.e., salvage treatment). However, since
October 2005 ADV has been approved for rescue therapy for
the treatment of emerging LAM-resistant HBV infection.
Entecavir was not included in the national health insurance
(NHI) reimbursement policies as a first-line anti-HBV
therapy until October 2008 in Taiwan. Before the start of
the treatment, serum creatinine, ALT, total bilirubin, HBV
serological markers (i.e., HBsAg, anti-HBs, anti-HBc,
HBeAg, and anti-HBe), and serum HBV DNA levels were
measured. The renal functions of the study participants
were monitored every month, liver function and HBV
serology were monitored every 3 months in HBeAg-positive
patients, and HBV DNA levels (using polymerase chain
reaction [PCR] assay) were monitored every 6 months or
whenever otherwise indicated (e.g., the presence of
a biochemical breakthrough) to confirm virological break-
throughs. A biochemical breakthrough is defined as an
increase in ALT above the upper limit of normal after
achieving normalization during continued treatment. A
virological breakthrough is defined as an increase in serum
HBV DNA by > 1 log10 (i.e., 10-fold) above nadir after
achieving a virological response during continued treat-
ment. Undetectable HBV DNA is defined as a level < 300
copies/mL, as determined using the Roche COBAS Amplicor
real-time PCR assay. To analyze LAM-resistant variants, the
polymerase gene containing the YMDD motif was amplified
using PCR. The presence of YMDD variants was further
confirmed by directly sequencing the PCR products. After
confirming the emergence of LAM-resistant mutants, rescue
therapy (either switching to or adding ADV), as determined
by the primary care physician, was initiated. The immu-
nosuppressive protocol was comprised of prednisolone,
cyclosporine, and mycophenolate mofetil.
Fourteen patients were identified as showing the
emergence of HBV-YMDD mutants. None of these patients
had cirrhosis of the liver or hepatocellular carcinoma. Five
patients were directly switched to ADV monotherapy. Nine
patients received ADV in addition to LAM combination
therapy. Data, including age, gender, HBeAg status, time
from transplantation to the initiation of LAM therapy,
duration of LAM therapy before the emergence of YMDD
mutants, HBV DNA levels, and liver enzyme levels before
rescue therapy, were recorded for each patient. The time
period from switching to or adding ADV to the clinical
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Figure 1 Clinical course of eight patients with decreased eGFR after adefovir-contained anti-HBV therapy.
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of 12 months or undetectable HBV DNA levels at the end of
12 or 24 months of rescue therapy, respectively) were
recorded and analyzed. The Roche COBAS Amplicor real-
time PCR assay, which has a lowest detection limit of 300
copies/mL, was used to detect virological breakthroughs.
All of these patients have been allowed to receive LAM plus
ADV therapy since May 2010 when the NHI reimbursement
policies were changed.
The serum levels of calcineurin inhibitors (CNIs) were
monitored every 3 months. Baseline and changes in renal
function during treatment were measured via the esti-
mated glomerular filtration rate (eGFR) using the
Cockcroft-Gault formula: [(140-age in years) (weight in
kilograms) (0.85, if female)/(72 serum creatinine in
mg/dL)] mL/min. If elevated serum creatinine or decreased
eGFR were found, the dosage of the CNI was adjusted
according to the serum CNI level. Renal biopsy was per-
formed to differentiate between graft rejection, CNI
toxicity, and other renal diseases in all of these patients. If
all other causes of nephrotoxicity were excluded, ADV-
related nephrotoxicity was considered. The ADV dosage
was adjusted according to the eGFR in any case of neph-
rotoxicity (Fig. 1).
All statistical analyses were performed using SPSS soft-
ware (SPSS for Windows, version 14.0; SPSS Inc., Chicago,
IL, USA). Quantitative data are summarized as the mean 
standard deviation (SD) or the median with the range, and
the categorical variables are presented as numbers and
percentages. The Student t test and Wilcoxon rank sum test
were used to compare continuous variables. Fisher’s exact
test was used to compare dichotomous variables. A p value
< 0.05 was considered statistically significant.This study was performed in accordance with the prin-
ciples of the 1983 Declaration of Helsinki and was approved
by the institutional review board in Chung Shan Medical
University Hospital.Results
Of the 14 patients included in this study, 11 were men and 3
were women. The mean age at the time of renal trans-
plantation was 46.8  11.5 years (range: 26e67 years; Table
1). Positive HBeAg status was determined in five patients
(35.7%) and negative HBsAg status was determined in nine
patients (64.3%). The mean interval from renal trans-
plantation to the start of LAMwas 13.8 11.8months (range:
0.8e46months). At the time of the initiation of LAM therapy,
the mean serum ALT level was 167.4  143.5 IU/mL (range:
39e503 IU/mL) and the median serum HBV DNA level was
8.02 log10 copies/mL (range: 5.80e9.54 log 10 copies/mL). At
the end of 12 months of initial LAM therapy, normalized ALT
levels were achieved in 11 patients and serum levels of HBV
DNA decreased to undetectable levels in four patients.
The mean period of LAM therapy before the occurrence
of a biochemical breakthrough and confirmation of the
emergence of resistant mutants was 23.3  10.4 months.
The specific primary mutations that confer resistance to
LAM included rtM204V þ rtL180M in six patients, rtM204I in
four patients, rtM204Iþ rtL180M in one patient, rtM204V/Iþ
rtL180M in one patient, rtM204V in one patient, and
rtM204V/I in one patient.
During the beginning of rescue therapy, the mean serum
ALT level was 142.2  99.8 IU/mL and the median serum
HBV DNA level was 7.85 log10 copies/mL (range: 5.01e9.23
Table 1 Characteristics of the study patients (n Z 14) at
initiation and follow-up of LAM therapy.
Characteristic (baseline) Patients (n Z14)
Gender (no.)
Male 11
Female 3
Mean age (y) (SD) 46.8 (11.5)
BMI (kg/m2) (range) 23.4 (17.8e32.5)
HBeAg (no.)
Positive 5
Negative 9
Initiation of LAM treatment
Mean time until initiation of
treatment (mo after
transplantation) (SD)
13.8 (11.8)
Mean ALT level (IU/L) (SD) 167.4 (143.5)
DNA level, median (log10
copies/mL) (range)
8.02 (5.80e9.54)
Mean time until ALT normalization
after treatment (wk) (SD)
17.0 (9.2)
Normalization of ALT after 12 mo
LAM treatment (no.)
11/14
Undetectable HBV DNA level after
12 months LAM treatment (no.)
4/14
ALT: alanine transaminase; BMI: body mass index; LAM: lam-
ivudine.
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therapy was 38.2  18.3 months. No significant difference
was observed in terms of ALT normalization, and unde-
tectable HBV DNA levels were observed in patients who
switched to ADV monotherapy and patients who received
LAM plus ADV combination therapy (Table 2). ALT normali-
zation was achieved in 13 patients (92.8%) by the end of the
12-month treatment period. After the sixth month, serum
HBV DNA levels in three patients (one in the ADV group and
two patients in LAM plus ADV group) declined to unde-
tectable levels. After 12 months of treatment, the medianTable 2 Characteristics of the study patients (n Z 14) at initia
Total (n Z
Mean age (y) 46.8
Mean duration of LAM therapy (mo) (SD) 23.3 (10.4)
Mean duration of rescue therapy (mo) (SD) 38.2 (18.3)
Mean baseline ALT (IU/L) (SD) 142.2 (99.8)
Positive HBeAg status (no.) 5
Median mutant HBV- DNA (log10 copes/mL) 7.85
Normalization of ALT after 12 mo (no.) 13
Undetectable HBV DNA level after 6 mo (no.) 3 /14
Undetectable HBV DNA level after 12 mo (no.) 5 /14
Undetectable HBV DNA level after 24 mo (no.) 6 /14
Undetectable HBV DNA level after 36 mo (no.) 5/7a
HBeAg seroconversion (no.) 1/5
ALT: alanine transaminase; LAM: lamivudine.
a Seven patients received follow-up examination for more than 36 mdecline in serum HBV DNA was 7.85 (5.01e9.23) to 4.36
(1.07e8.02) log10 copies/mL (median decline of -4.02
log10), and five patients (one in the ADV group and four
patients in the LAM plus ADV group) demonstrated unde-
tectable serum levels. After 24 months of treatment, six
patients (one in the ADV group and five patients in the LAM
plus ADV group) achieved undetectable serum levels. Seven
patients were followed for more than 36 months, and five
of these achieved undetectable serum HBV DNA levels. The
mean follow-up duration of ADV monotherapy was 32.8
months, and the longest period was 71 months. No viro-
logical breakthroughs were observed during the follow-up
period in either group. One of the five HBeAg-positive
patients achieved HBeAg seroconversion.
Renal dysfunction was diagnosed in eight patients
(57.2%) during the follow-up period (Table 3). A mild
decrease in eGFR (5e20%) from the baseline was observed
in four patients, a moderate decrease (20e30%) was noted
in two patients, and a severe decrease (> 30%) was noted in
two patients. Among these, graft rejection was verified in
two patients by renal biopsy. CNI toxicity was considered to
be the cause of nephrotoxicity in two patients, and the use
of immunosuppressive agents was adjusted accordingly.
Nephrotoxicity led to a decrease in ADV dosage in three
patients (eGFR diminished to 30e50 mL/minute) and with-
drawal in one patient (eGFR < 20 mL/min).Discussion
Although entecavir therapy is safe and efficient for treating
HBV-positive organ transplant patients and prophylaxis of
HBV reactivation,11 LAM is the most promising agent for the
treatment of HBsAg-positive renal transplant recipients in
Asian countries.5 In our study, in accordance with the NHI
reimbursement policies that were in effect during the study
period, LAM was not introduced prior to prophylaxis or right
after renal transplantation (pre-emptive) until a flare up of
hepatitis. By that time, the serum HBV DNA level would be
rather high (median: 8.02 log10 copies/mL), and only 28.5%
of patients (in comparison with > 60% of immunocompetent
HBV carriers) achieved undetectable serum HBV DNA levelstion and follow-up of ADV rescue therapy.
14) ADV (n Z 5) ADV plus LAM (n Z 9) p
46.2 47.1 0.89
25.1 (22.5) 22.2 (5.4) 0.64
32.8 (9.2) 41.2 (12.6) 0.5
93.0 (41.7) 169.5 (79 9) 0.18
1 4 0.37
7.88 7.82 0.87
4/5 9/9 0.35
1/5 2/9 0.72
1/5 4/9 0.37
1/5 5/9 0.25
1/1 4/6
0/1 1/4
onths.
Table 3 Renal functions of the study patients before and after the administration of adefovir dipivoxil.
Case
no.
Donor of
transplant
Rescue
therapy
Dosage of
adefovir
(mg/d)
Peak level of
CNIa (ng/mL)
Creatine
before ADV
(mg/dL)
eGFR before
ADV (mL/min)
Creatine
after ADV
(mg/dL)
eGFR after
ADV (mL/min)
6 eGFR
(mL/min)
1 cadaver add on 10 389.9 (cycl) 1.2 67.2 1.1 73.3 6.1
2 live add on 10 6.4 (tacro) 1.2 89.7 1.1 97.8 8.1
3 cadaver add on 5 8.2 (tacro) 2.5 22.8 4.3 13.3 9.5
4 live add on 5 7.6 (tacro) 0.9 61.9 2.2 25.3 36.6
5 live add on 5 5.8 (tacro) 1.3 64.7 1.4 60.1 4.6
6 live add on 10 6.2 (tacro) 1.2 66.1 1.5 52.8 13.3
7 live add on 10 5.8 (tacro) 1 130.5 1.0 130.5 0
8 cadaver add on 10 770.3 (cycl) 0.8 63.0 1.0 50.4 12.6
9 live add on 5 6.9 (tacro) 1.7 51.2 1.6 54.4 3.2
10 cadaver switch 10 9.6 (tacro) 1.2 79.8 1.1 87.1 7.3
11 live switch 10 5.9 (tacro) 1.0 82.6 1.3 63.5 19.1
12 live switch 5 686.9 (cycl) 1.0 58.8 1.1 53.4 5.4
13 cadaver switch 5 6.2 (tacro) 1.5 56.2 1.6 52.7 3.5
14 live switch 5 7.8 (tacro) 1.4 68.4 1.3 73.6 5.2
a CNI: calcineurin inhibitor; cycl: cyclosporine; tacro: tacrolimus.
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overall cumulative YMDD mutation rate was 51.8% (14/27)
after 23 months of follow-up, which is higher than most
other studies. Therefore, it seems better to initiate LAM
therapy immediately after renal transplantation, rather
than later, when rapid viral replication and overt liver
disease have already developed in order to prevent the
emergence of YMDD mutants.
The ADV resistance rate in patients with LAM resistance
can be greatly reduced by addingdrather than switching
todADV.9,10 However, to date, no data on the effectiveness
and resistance to ADV are available on HBV-positive renal
transplant recipients. In this retrospective study, after
a mean follow-up period of 38.2 months we found that
a decline in HBV DNA levels of up to 4 log10 copies/mL could
be obtained after 12 months of treatment. Patients who
received LAM plus ADV anti-HBV therapy seemed more likely
achieve undetectable serum HBV DNA levels after 12, 24,
and 36 months (4/9 [44.4%], 6/9 [66.7%], and 4/6 [66.7%],
respectively) in comparison with those who received ADV
monotherapy; however, mainly due to the small number of
cases in this study, these difference are not statistically
significant. The decline in the serum HBV DNA level in the
ADV monotherapy group was slower than that observed in
the combination group, but there were no virological
breakthroughs observed in either groups during the study
period. In the study by Haziyannis et al,12 after treatment
with adefovir dipivoxil for up to 240 weeks to treat HBeAg-
negative chronic HBV patients, the cumulative probability
of mutations with virological resistance was 20%, but this
probability was only 3% after 96 weeks. Prolonged therapy is
associated with the emergence of drug resistance following
antiviral treatment for chronic HBV, which usually negates
the treatment benefits.13,14 It is essential to monitor viro-
logical breakthroughs, especially in patients receiving ADV
monotherapy, if anti-HBV therapy is to be extended.
The long-term use of ADV has been reported to be asso-
ciated with a potential risk of nephrotoxicity.15,16 In fact,
nephrotoxicity is listed as a warning in association with ADV.
Graft rejection and the nephrotoxic effects of CNIs (i.e.,cyclosporine and tacrolimus) are also major concerns
following solid organ transplantation and represent major
challenges to patient survival.17 All of our patients also
received CNI-based immunosuppressive therapy after renal
transplantation. About 29% of these patients developed
moderate to severe renal insufficiency during the follow-up
period, and four patients had to decrease or stop ADV
therapydue tonephrotoxicity. Thismay limit the therapeutic
efficacy of ADV for the treatment of HBV infection. It is
mandatory to closely monitor the renal function of patients
receiving combination ADV plus CNI-based immunosuppres-
sive therapy. Switching to new anti-HBV agents with higher
genetic barriers and lowernephrotoxicity is recommended to
ameliorate the progression of renal insufficiency.
There are some limitations to our study. First, the
enrolled population was small and heterogeneous. This is
mainly because the strategy for treating LAM-resistant
mutants was not standardized during the study period
(before 2008). Second, the mean follow-up duration was
not long enough to observe the emergence of ADV-resistant
mutants because all of the patients were allowed to receive
LAM plus ADV therapy since May 2010 when the NHI reim-
bursement policies were changed.
In conclusion, although no statistical difference was
noted, ADV plus LAM combination therapy tends to result in
higher therapeutic efficacy over ADV monotherapy for the
treatment of LAM-resistant HBV infection in renal trans-
plant recipients. No virological breakthroughs were noted
in our patients during the follow-up period; however,
nephrotoxicity may limit the therapeutic usefulness of ADV
in a significant proportion of patients who have renal
dysfunction. Larger clinical trials are needed to confirm
these preliminary results.References
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